283 related articles for article (PubMed ID: 16144933)
1. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
Nikpour M; Pellagatti A; Liu A; Karimi M; Malcovati L; Gogvadze V; Forsblom AM; Wainscoat JS; Cazzola M; Zhivotovsky B; Grandien A; Boultwood J; Hellström-Lindberg E
Br J Haematol; 2010 Jun; 149(6):844-54. PubMed ID: 20408843
[TBL] [Abstract][Full Text] [Related]
4. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts.
Schmidt-Mende J; Tehranchi R; Forsblom AM; Joseph B; Christensson B; Fadeel B; Zhivotovsky B; Hellström-Lindberg E
Leukemia; 2001 May; 15(5):742-51. PubMed ID: 11368434
[TBL] [Abstract][Full Text] [Related]
6. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.
Tehranchi R; Fadeel B; Forsblom AM; Christensson B; Samuelsson J; Zhivotovsky B; Hellstrom-Lindberg E
Blood; 2003 Feb; 101(3):1080-6. PubMed ID: 12393561
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Kasper C; Zahner J; Sayer HG
J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
11. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells.
Rigolin GM; Porta MD; Ciccone M; Bugli AM; Bragotti LZ; Mauro E; Fraulini C; Rossi AR; Bardi A; Cuneo A; Castoldi G
Br J Haematol; 2004 Aug; 126(4):501-7. PubMed ID: 15287942
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells.
Chakraborty A; Guha S
Urology; 2007 Jun; 69(6):1210-5. PubMed ID: 17572226
[TBL] [Abstract][Full Text] [Related]
13. Multicenter prospective study of clonal complications in adult aplastic anemia patients following recombinant human granulocyte colony-stimulating factor (lenograstim) administration.
Bessho M; Hotta T; Ohyashiki K; Takahashi T; Mizoguchi H; Asano S; Ikeda Y; Sakurai M; Tojo A; Kizaki M; Iwanaga M; Tomonaga M; Hirashima K
Int J Hematol; 2003 Feb; 77(2):152-8. PubMed ID: 12627850
[TBL] [Abstract][Full Text] [Related]
14. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
16. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts.
Ramirez JM; Schaad O; Durual S; Cossali D; Docquier M; Beris P; Descombes P; Matthes T
Br J Haematol; 2009 Jan; 144(2):251-62. PubMed ID: 19036111
[TBL] [Abstract][Full Text] [Related]
17. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
Tehranchi R; Invernizzi R; Grandien A; Zhivotovsky B; Fadeel B; Forsblom AM; Travaglino E; Samuelsson J; Hast R; Nilsson L; Cazzola M; Wibom R; Hellström-Lindberg E
Blood; 2005 Jul; 106(1):247-53. PubMed ID: 15755901
[TBL] [Abstract][Full Text] [Related]
18. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
[TBL] [Abstract][Full Text] [Related]
20. Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria.
Houwerzijl EJ; Pol HW; Blom NR; van der Want JJ; de Wolf JT; Vellenga E
Leukemia; 2009 May; 23(5):886-91. PubMed ID: 19148135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
